Refining estimates of prescription durations by using observed covariates in pharmacoepidemiological databases: an application of the reverse waiting time distribution-Reference-Cited by-同舟云学术

Refining estimates of prescription durations by using observed covariates in pharmacoepidemiological databases: an application of the reverse waiting time distribution

Published:2017-05-03 Issue:8 Volume:26 Page:900-908
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Støvring Henrik¹^ORCID,Pottegård Anton²^ORCID,Hallas Jesper²^ORCID

Affiliation:

1. Biostatistics, Department of Public Health; Aarhus University; Aarhus Denmark

2. Clinical Pharmacology and Pharmacy, Department of Public Health; University of Southern Denmark; Odense Denmark

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pds.4216/fullpdf

Reference19 articles.

1. Comparison of different methods to estimate prevalence of drug use by using pharmacy records;Mantel-Teeuwisse;J Clin Epidemiol,2001

2. Counting drugs to understand the disease: the case of measuring the diabetes epidemic;Støvring;Popul Health Metrics,2007

3. Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length;Gardarsdottir;J Clin Epidemiol,2010

4. Estimating the effect of current, previous and never use of drugs in studies based on prescription registries;Nielsen;Pharmacoepidemiol Drug Saf,2009

5. Comparison of alternative models for linking drug exposure with adverse effects;Abrahamowicz;Stat Med,2011

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative retention and effectiveness of migraine preventive treatments: A nationwide registry‐based cohort study;European Journal of Neurology;2023-09-27

2. Core concepts in pharmacoepidemiology: Measurement of medication exposure in routinely collected healthcare data for causal inference studies in pharmacoepidemiology;Pharmacoepidemiology and Drug Safety;2023-09-26

3. Prenatal Antidepressant Exposure and the Risk of Attention-Deficit/Hyperactivity Disorder in Childhood: Accounting for Misclassification of Exposure;Epidemiology;2023-03-27

4. A data‐informed approach using individualised dispensing patterns to estimate medicine exposure periods and dose from pharmaceutical claims data;Pharmacoepidemiology and Drug Safety;2022-11-30

5. Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs;European Heart Journal Open;2022-10-27